H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $100 from $60 and keeps a Buy rating on the shares following the Q3 report. Considering the annual price range of Syfovre and Izerway between $13,000 and $26,000, the firm updated its projected price for tinlarebant from $6,000 to $9,500 in the model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE: